Avory & Company LLC lessened its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 5.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 241,206 shares of the company's stock after selling 12,926 shares during the period. Omnicell makes up approximately 6.0% of Avory & Company LLC's portfolio, making the stock its 6th biggest holding. Avory & Company LLC owned 0.52% of Omnicell worth $10,738,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. Proficio Capital Partners LLC bought a new position in Omnicell during the fourth quarter valued at about $1,542,000. M&T Bank Corp boosted its stake in Omnicell by 51.2% in the fourth quarter. M&T Bank Corp now owns 25,934 shares of the company's stock valued at $1,155,000 after acquiring an additional 8,786 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after acquiring an additional 377,883 shares during the last quarter. Keybank National Association OH grew its position in shares of Omnicell by 32.1% during the 4th quarter. Keybank National Association OH now owns 8,902 shares of the company's stock valued at $396,000 after acquiring an additional 2,161 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Omnicell by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company's stock worth $27,431,000 after purchasing an additional 21,157 shares during the last quarter. 97.70% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
OMCL has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Benchmark reiterated a "buy" rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company decreased their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a report on Thursday. Finally, Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $52.33.
Get Our Latest Analysis on Omnicell
Omnicell Price Performance
NASDAQ OMCL traded down $1.05 during trading hours on Monday, hitting $35.94. The company had a trading volume of 476,876 shares, compared to its average volume of 491,461. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 133.12, a PEG ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75. The firm has a 50 day simple moving average of $41.74 and a 200 day simple moving average of $43.64.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Insider Transactions at Omnicell
In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.64% of the company's stock.
Omnicell Company Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
